Celecoxib induces adipogenic differentiation of hemangioma‑derived mesenchymal stem cells through the PPAR‑γ pathway <em>in vitro</em> and <em>in vivo</em>

Wang,Yuan; Kong,Liangliang; Sun,Buhao; Cui,Jie; Shen,Weimin

doi:10.3892/etm.2022.11303

Celecoxib induces adipogenic differentiation of hemangioma‑derived mesenchymal stem cells through the PPAR‑γ pathway in vitro and in vivo

Authors:
- Yuan Wang
- Liangliang Kong
- Buhao Sun
- Jie Cui
- Weimin Shen
View Affiliations

Affiliations: Department of Burns and Plastic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu 210008, P.R. China
Published online on: April 7, 2022 https://doi.org/10.3892/etm.2022.11303
Article Number: 375
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Infantile hemangioma (IH) is a benign tumor that produces a permanent scar or a mass of fibro‑fatty tissue after involution in 40‑80% of cases. Celecoxib is an inhibitor of cyclooxygenase‑2 (COX‑2), and can inhibit angiogenesis and fibrosis. The present study aimed to clarify whether celecoxib is able to induce tumor regression with minimal side effects. For that purpose, the regulation of celecoxib in the involution of IH was investigated in an IH model. Hemangioma‑derived mesenchymal stem cells (Hem‑MSCs) were isolated from proliferating specimens, and an IH model was established by injecting these cells into nude mice. Celecoxib was administered in vitro and in vivo. Oil Red O staining and reverse transcription‑quantitative‑PCR were used to detect the adipogenic differentiation of Hem‑MSCs. Histologic analysis and immunohistochemical staining of the tumor xenografts were performed to investigate the pathological evolution of the tumor. The results showed that celecoxib inhibited the proliferation and induced the adipogenic differentiation of Hem‑MSCs in vitro. In vivo, adipocytes were only present in the celecoxib group at week 4, while a larger number of fibroblasts and collagenous fibers could be observed in the basic fibroblast growth factor group. Therefore, celecoxib may be a potential agent used for IH treatment by inducing adipogenesis and inhibiting fibroblast formation.

View Figures

View References

1	You Y, Li Y, Xiao Y and Zhang J: Propranolol vs. steroids in the treatment of infantile hemangiomas: A meta-analysis. Mol Clin Oncol. 15(156)2021.PubMed/NCBI View Article : Google Scholar
2	Wang Q, Xiang B, Chen S and Ji Y: Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. Australas J Dermatol. 60:181–185. 2019.PubMed/NCBI View Article : Google Scholar
3	Satterfield KR and Chambers CB: Current treatment and management of infantile hemangiomas. Surv Ophthalmol. 64:608–618. 2019.PubMed/NCBI View Article : Google Scholar
4	Itinteang T, Vishvanath A, Day DJ and Tan ST: Mesenchymal stem cells in infantile haemangioma. J Clin Pathol. 64:232–236. 2011.PubMed/NCBI View Article : Google Scholar
5	Ji Y, Chen S, Li K, Li L, Xu C and Xiang B: Signaling pathways in the development of infantile hemangioma. J Hematol Oncol. 7(13)2014.PubMed/NCBI View Article : Google Scholar
6	Koki AT and Masferrer JL: Celecoxib: A specific COX-2 inhibitor with anticancer properties. Cancer Control. 9:28–35. 2002.PubMed/NCBI View Article : Google Scholar
7	Xie C, Xu X, Wang X, Wei S, Shao L, Chen J, Cai J and Jia L: Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E₂. Oncol Lett. 16:940–948. 2018.PubMed/NCBI View Article : Google Scholar
8	Li J, Hao Q, Cao W, Vadgama JV and Wu Y: Celecoxib in breast cancer prevention and therapy. Cancer Manag Res. 10:4653–4667. 2018.PubMed/NCBI View Article : Google Scholar
9	Li F, Fan C, Zeng B, Zhang C, Chai Y, Liu S and Ouyang Y: Celecoxib suppresses fibroblast proliferation and collagen expression by inhibiting ERK1/2 and SMAD2/3 phosphorylation. Mol Med Rep. 5:827–831. 2012.PubMed/NCBI View Article : Google Scholar
10	Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L and Keely P: COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res. 18(35)2016.PubMed/NCBI View Article : Google Scholar
11	Oak NR, Gumucio JP, Flood MD, Saripalli AL, Davis ME, Harning JA, Lynch EB, Roche SM, Bedi A and Mendias CL: Inhibition of 5-LOX, COX-1, and COX-2 increases tendon healing and reduces muscle fibrosis and lipid accumulation after rotator cuff repair. Am J Sports Med. 42:2860–2868. 2014.PubMed/NCBI View Article : Google Scholar
12	Yuan SM, Guo Y, Zhou XJ, Shen WM and Chen HN: Rosiglitazone accentuates the adipogenesis of hemangioma-derived mesenchymal stem cells induced by adipogenic media. Int J Clin Exp Med. 7:1741–1746. 2014.PubMed/NCBI
13	Yu XW, Wei D, Gao YS, Du HZ, Yu BY, Li RM, Qian CM, Luo XJ, Yuan ST, Wang JS and Sun L: Synergistic combination of DT-13 and Topotecan inhibits aerobic glycolysis in human gastric carcinoma BGC-823 cells via NM IIA/EGFR/HK II axis. J Cell Mol Med. 23:6622–6634. 2019.PubMed/NCBI View Article : Google Scholar
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
15	Yuan SM, Guo Y, Wang Q, Xu Y, Wang M, Chen HN and Shen WM: Over-expression of PPAR-γ2 gene enhances the adipogenic differentiation of hemangioma-derived mesenchymal stem cells in vitro and in vivo. Oncotarget. 8:115817–115828. 2017.PubMed/NCBI View Article : Google Scholar
16	Chu TH, Chan HH, Kuo HM, Liu LF, Hu TH, Sun CK, Kung ML, Lin SW, Wang EM, Ma YL, et al: Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. Oncotarget. 5:1475–1490. 2014.PubMed/NCBI View Article : Google Scholar
17	Atiakshin D, Buchwalow I and Tiemann M: Mast cells and collagen fibrillogenesis. Histochem Cell Biol. 154:21–40. 2020.PubMed/NCBI View Article : Google Scholar
18	Chen L, Li J, Zhang J, Dai C, Liu X, Wang J, Gao Z, Guo H, Wang R, Lu S, et al: S100A4 promotes liver fibrosis via activation of hepatic stellate cells. J Hepatol. 62:156–164. 2015.PubMed/NCBI View Article : Google Scholar
19	Wnęk A, Andrzejewska E, Kobos J, Taran K and Przewratil P: Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment. Immunol Lett. 185:27–31. 2017.PubMed/NCBI View Article : Google Scholar
20	Yuan SM, Chen RL, Chen HN, Shen WM and Zhou XJ: The role of the expression of PPAR-gamma gene in the adipogenesis in hemangioma evolution. Zhonghua Zheng Xing Wai Ke Za Zhi. 29:45–48. 2013.PubMed/NCBI(In Chinese).
21	Ishay-Ronen D, Diepenbruck M, Kalathur RKR, Sugiyama N, Tiede S, Ivanek R, Bantug G, Morini MF, Wang J, Hess C and Christofori G: Gain fat-lose metastasis: Converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell. 35:17–32.e6. 2019.PubMed/NCBI View Article : Google Scholar
22	Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, To TKJ, Schug Z, Basu S, Wang F, et al: Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 569:73–78. 2019.PubMed/NCBI View Article : Google Scholar
23	Tian F, Zhang YJ and Wang YH: Effects of celecoxib on expression of PPARγ and NF-κB in type 2 diabetes rats with non-alcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi. 24:590–595. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
24	Lima LH, Farah ME, Gum G, Ko P and de Carvalho RAP: Sustained and targeted episcleral delivery of celecoxib in a rabbit model of retinal and choroidal neovascularization. Int J Retina Vitreous. 4(31)2018.PubMed/NCBI View Article : Google Scholar
25	Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M and Vogt T: Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep. 19:547–553. 2008.PubMed/NCBI
26	Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR and Corbett JA: Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: Evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes. 49:346–355. 2000.PubMed/NCBI View Article : Google Scholar
27	Harbi S, Wang R, Gregory M, Hanson N, Kobylarz K, Ryan K, Deng Y, Lopez P, Chiriboga L and Mignatti P: Infantile hemangioma originates from a dysregulated but not fully transformed multipotent stem cell. Sci Rep. 6(35811)2016.PubMed/NCBI View Article : Google Scholar
28	Li HH, Lou Y, Zhang RR, Xie J and Cao DS: Propranolol accelerats hemangioma stem cell transformation into adipocyte. Ann Plast Surg. 83:e5–e13. 2019.PubMed/NCBI View Article : Google Scholar
29	England RW, Hardy KL, Kitajewski AM, Wong A, Kitajewski JK, Shawber CJ and Wu JK: Propranolol promotes accelerated and dysregulated adipogenesis in hemangioma stem cells. Ann Plast Surg. 73 (Suppl 1):S119–S124. 2014.PubMed/NCBI View Article : Google Scholar
30	Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64:2030–2038. 2004.PubMed/NCBI View Article : Google Scholar
31	Knopfová L and Smarda J: The use of Cox-2 and PPARγ signaling in anti-cancer therapies. Exp Ther Med. 1:257–264. 2010.PubMed/NCBI View Article : Google Scholar
32	Mingyuan X, Qianqian P, Shengquan X, Chenyi Y, Rui L, Yichen S and Jinghong X: Hypoxia-inducible factor-1α activates transforming growth factor-β1/Smad signaling and increases collagen deposition in dermal fibroblasts. Oncotarget. 9:3188–3197. 2017.PubMed/NCBI View Article : Google Scholar
33	Ma Y, Kakudo N, Morimoto N, Lai F, Taketani S and Kusumoto K: Fibroblast growth factor-2 stimulates proliferation of human adipose-derived stem cells via Src activation. Stem Cell Res Ther. 10(350)2019.PubMed/NCBI View Article : Google Scholar
34	Yang Y, Xia T, Zhi W, Wei L, Weng J, Zhang C and Li X: Promotion of skin regeneration in diabetic rats by electrospun core-sheath fibers loaded with basic fibroblast growth factor. Biomaterials. 32:4243–4254. 2011.PubMed/NCBI View Article : Google Scholar
35	Li F, Liu S, Ouyang Y, Fan C, Wang T, Zhang C, Zeng B, Chai Y and Wang X: Effect of celecoxib on proliferation, collagen expression, ERK1/2 and SMAD2/3 phosphorylation in NIH/3T3 fibroblasts. Eur J Pharmacol. 678:1–5. 2012.PubMed/NCBI View Article : Google Scholar
36	Fairweather M, Heit YI, Buie J, Rosenberg LM, Briggs A, Orgill DP and Bertagnolli MM: Celecoxib inhibits early cutaneous wound healing. J Surg Res. 194:717–724. 2015.PubMed/NCBI View Article : Google Scholar
37	Olson JM, Haas AW, Lor J, McKee HS and Cook ME: A comparison of the anti-inflammatory effects of Cis-9, trans-11 conjugated linoleic acid to celecoxib in the collagen-induced arthritis model. Lipids. 52:151–159. 2017.PubMed/NCBI View Article : Google Scholar
38	Salib CG, Reina N, Trousdale WH, Limberg AK, Tibbo ME, Jay AG, Robin JX, Turner TW, Jones CR, Paradise CR, et al: Inhibition of COX-2 pathway as a potential prophylaxis against arthrofibrogenesis in a rabbit model of joint contracture. J Orthop Res. 37:2609–2620. 2019.PubMed/NCBI View Article : Google Scholar